Lung Cancer Genomic Testing Market - Global Forecast 2026-2032

The lung cancer genomic testing market is transforming precision oncology with rapid adoption of advanced diagnostics and individualized therapy approaches. Senior decision-makers require clear intelligence to address this evolving sector shaped by regulatory shifts, emerging technologies, and changing care models.

Market Snapshot: Lung Cancer Genomic Testing Market

The Lung Cancer Genomic Testing Market expanded from USD 1.16 billion in 2025 to USD 1.26 billion in 2026 and is anticipated to achieve robust growth at a CAGR of 8.58%, reaching USD 2.07 billion by 2032. This advancement reflects strong adoption across clinical environments and a mounting emphasis on precision diagnostics, with increasing market penetration in research, hospital, and laboratory settings worldwide.

Lung Cancer Genomic Testing Market Scope & Segmentation

This analysis explores the integrated landscape of lung cancer genomic testing by examining technology innovations, clinical adoption, and regional dynamics. Key segments are delineated by technological application, diagnostic approach, clinical utility, end-user environment, and global region, informing both investment and implementation strategies.

Technology Platforms: Next-Generation Sequencing (NGS), Real-Time Polymerase Chain Reaction (RT-PCR), Sanger Sequencing, Microarray, and Fluorescence In Situ Hybridization (FISH) support multiple phases from biomarker discovery to clinical confirmation, enhancing accuracy and workflow efficiency.
Test Modalities: Liquid biopsy methods enable minimally invasive and serial patient monitoring, while tissue-based techniques, such as fine needle aspiration and histopathology, ensure comprehensive tumor characterization when sample requirements are critical.
Clinical Applications: Includes companion diagnostics for targeted therapies, predictive and prognostic testing for patient risk stratification, as well as monitoring protocols that guide longitudinal treatment adjustments and clinical trial enrolment.
End-User Settings: Academic and research institutes, hospitals, diagnostic laboratories, and organizations in the pharmaceutical and biotechnology sector are amplifying the utility and reach of these testing solutions under diverse care and research mandates.
Regions: The Americas, Europe, Middle East & Africa, and Asia-Pacific drive differential growth, shaped by distinct regulatory requirements, healthcare infrastructure maturity, and levels of genomic research investment.

Key Takeaways for Decision-Makers

Genomic testing is advancing from isolated diagnostic practice to an integrated approach for ongoing patient care, supporting targeted interventions throughout the treatment journey.
Innovation in technology—especially broader adoption of NGS and sophisticated bioinformatics—yields higher detection reliability and accelerates result delivery, improving clinical decision timelines.
Regulatory environment clarity, with a focus on companion diagnostic validation, is shortening the pathway to clinical implementation and fostering market entry across regions.
Market traction is governed by more than technological capability; clinician experience, operational realities in laboratories, reimbursement structures, and partnership integration are all shaping adoption rates.
Widespread use of liquid biopsy and other minimally invasive techniques is broadening patient access and supporting continuous disease management, especially when tissue collection is difficult.
Strategic alliances and market consolidation are influencing how providers and manufacturers achieve scalability, maintain workflow continuity, and ensure sustainable operations.

Tariff Impact and Supply Chain Considerations

Following United States tariff actions in 2025, supply chains involved in lung cancer genomic testing have become more complex. These developments have introduced cost pressures and uncertainties within procurement, resulting in laboratories and manufacturers diversifying suppliers, expanding inventory reserves, and adapting sourcing models. Organizations are strengthening interest in regional production, enhancing contract flexibility for essential reagents and equipment, and prioritizing safeguards for service continuity in clinical operations.

Methodology & Data Sources

The findings are based on expert primary interviews, in-depth secondary research, and a systematic technical review. Cross-validation with laboratory directors, clinical oncology professionals, and regulatory experts ensures data transparency and decision-making reliability for C-suite executives and operational leaders.

Why This Report Matters

Provides senior decision-makers—including business development heads and clinical operations executives—with actionable insights to align technology investments with evolving clinical and operational needs.
Delivers a strategic understanding of market and regulatory developments that influence risk assessment, testing program adoption, and partnership strategies in genomic diagnostics.
Equips stakeholders to anticipate changes in reimbursement models, adapt to regional adoption trends, and ensure multidisciplinary readiness for future growth or disruption.

Conclusion

Lung cancer genomic testing is elevating diagnostic accuracy, transforming operational frameworks, and driving new models of industry partnership. Enduring value lies in strategic technology selection, resilient supply chains, and collaborative evidence generation for improved patient and institutional outcomes.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Genomic Testing Market, by Technology

8.1. Fluorescence In Situ Hybridization
8.2. Microarray
8.3. Next Generation Sequencing
8.3.1. Targeted Sequencing
8.3.2. Whole Exome Sequencing
8.3.3. Whole Genome Sequencing
8.4. Real Time Polymerase Chain Reaction
8.5. Sanger Sequencing

9. Lung Cancer Genomic Testing Market, by Test Type

9.1. Liquid Biopsy
9.1.1. Circulating Tumor Cells
9.1.2. Circulating Tumor Dna
9.2. Tissue Biopsy
9.2.1. Fine Needle Aspiration
9.2.2. Tissue Section

10. Lung Cancer Genomic Testing Market, by Application

10.1. Companion Diagnostics
10.2. Predictive Testing
10.3. Prognostic Testing
10.4. Treatment Monitoring

11. Lung Cancer Genomic Testing Market, by End User

11.1. Academic And Research Institutes
11.2. Hospitals And Diagnostic Laboratories
11.3. Pharmaceutical And Biotechnology Companies

12. Lung Cancer Genomic Testing Market, by Region

12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific

13. Lung Cancer Genomic Testing Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Lung Cancer Genomic Testing Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. United States Lung Cancer Genomic Testing Market
16. China Lung Cancer Genomic Testing Market

17. Competitive Landscape

17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Abbott Laboratories
17.6. Admera Health
17.7. Agilent Technologies, Inc.
17.8. BGI
17.9. CD Genomics
17.10. CeGaT GmbH
17.11. Centogene N.V.
17.12. F. Hoffmann-La Roche AG
17.13. Illumina, Inc.
17.14. Laboratory Corporation of America Holdings
17.15. NeoGenomics Laboratories
17.16. OncoDNA
17.17. OPKO Health, Inc.
17.18. QIAGEN N.V.
17.19. Quest Diagnostics Incorporated
17.20. Thermo Fisher Scientific, Inc.
17.21. Veracyte, Inc.

List of Figures

FIGURE 1. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 107. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 108. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 109. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 110. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 112. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 123. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 124. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 125. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 126. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 127. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 128. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 140. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 141. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 142. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 143. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 144. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 145. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 148. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 149. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 150. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 151. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 152. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 153. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 164. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 165. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 166. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 167. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 168. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 169. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 172. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 173. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 174. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 175. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 176. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 177. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 178. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 179. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 180. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 181. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 182. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 183. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 184. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 185. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 189. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 190. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 191. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 192. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 196. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 197. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 198. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 199. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
TABLE 200. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2032 (USD MILLION)
TABLE 201. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 202. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Lung Cancer Genomic Testing market report include:

Abbott Laboratories
Admera Health
Agilent Technologies, Inc.
BGI
CD Genomics
CeGaT GmbH
Centogene N.V.
F. Hoffmann-La Roche AG
Illumina, Inc.
Laboratory Corporation of America Holdings
NeoGenomics Laboratories
OncoDNA
OPKO Health, Inc.
QIAGEN N.V.
Quest Diagnostics Incorporated
Thermo Fisher Scientific, Inc.
Veracyte, Inc.

Table Information

Report Attribute	Details
No. of Pages	183
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 1.26 Billion
Forecasted Market Value ( USD ) by 2032	$ 2.07 Billion
Compound Annual Growth Rate	8.5%
Regions Covered	Global
No. of Companies Mentioned	18

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3511EUR$3,939USD£3,045GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3787EUR$4,249USD£3,285GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5133EUR$5,759USD£4,452GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6212EUR$6,969USD£5,387GBP

Market Snapshot: Lung Cancer Genomic Testing Market

Lung Cancer Genomic Testing Market Scope & Segmentation

Key Takeaways for Decision-Makers

Tariff Impact and Supply Chain Considerations

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Molecular Oncology Diagnostics Market - Global Forecast 2026-2032

Cancer/Tumor Profiling Market - Global Forecast 2025-2032

Next Generation Cancer Diagnostics Global Market Report 2025

Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market Size. With Executive and Consultant Guides

Cancer Profiling Market Report 2025